Medtech Investment Working Group – Q2 Meeting

WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen (D-N.H.) and U.S. Reps. Kevin Hern (R-Okla.) and Mike Thompson (D-Calif.). The bill provides for Medicare and Medicaid coverage of evidence-based software applications used to prevent, manage, or treat medical conditions.

EPAM recently published a case study highlighting the rise of composable commerce solutions to enable B2B processes in the healthcare industry. This piece focuses on the experience of diagnostics company, Cepheid – a part of Danaher Corporation.

AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.

AdvaMed®’s medtech priorities for the 119th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.

Learn how the EY Clinical Trial Fast Lane solution helps jumpstart clinical trials in 45 to 60 working days through rapid performance of functional services, deep understanding of clinical trial operations, and more.

AdvaMed®, the Medtech Association, released the following statement from President and CEO Scott Whitaker upon the passage of a research and development expensing tax provision critical to medtech innovation in the House of Representatives.

Scott Whitaker, president and CEO of AdvaMed®, the Medtech Association, today urged Congress to enact a research and development expensing tax provision critical to medtech innovation. The provision would delay a change requiring businesses to deduct their research and development expenses over five years, allowing immediate deduction.

Are you an AdvaMed® member and attending the upcoming J.P. Morgan Healthcare Conference and looking for a place to hold meetings?